Nigrosome 1 imaging: technical considerations and clinical applications.
暂无分享,去创建一个
Eung Yeop Kim | Jongho Lee | Young Hee Sung | E. Kim | Jongho Lee | Y. Sung
[1] Yoshiharu Tamakawa,et al. The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. , 2002, AJNR. American journal of neuroradiology.
[2] B. Bloem,et al. Susceptibility-Weighted Imaging Improves the Diagnostic Accuracy of 3T Brain MRI in the Work-Up of Parkinsonism , 2015, American Journal of Neuroradiology.
[3] S. Kang,et al. Loss of Substantia Nigra Hyperintensity at 3.0-T MR Imaging in Idiopathic REM Sleep Behavior Disorder: Comparison with 123I-FP-CIT SPECT. , 2017, Radiology.
[4] N. Wang,et al. Using ‘swallow-tail’ sign and putaminal hypointensity as biomarkers to distinguish multiple system atrophy from idiopathic Parkinson’s disease: A susceptibility-weighted imaging study , 2017, European Radiology.
[5] J. J. Lee,et al. Correlation of 3D FLAIR and Dopamine Transporter Imaging in Patients With Parkinsonism. , 2016, AJR. American journal of roentgenology.
[6] P Sandroni,et al. Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.
[7] R. Bowtell,et al. Visualization of nigrosome 1 and its loss in PD , 2013, Neurology.
[8] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[9] Z. Cho,et al. Seven‐tesla magnetic resonance images of the substantia nigra in Parkinson disease , 2012, Annals of neurology.
[10] Ji Young Yun,et al. Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With 123I‐FP‐CIT SPECT , 2016, Movement disorders : official journal of the Movement Disorder Society.
[11] D. Auer,et al. Protocol of a single group prospective observational study on the diagnostic value of 3T susceptibility weighted MRI of nigrosome-1 in patients with parkinsonian symptoms: the N3iPD study (nigrosomal iron imaging in Parkinson’s disease) , 2017, BMJ Open.
[12] A. M. Ortiz,et al. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[13] Martin Styner,et al. Imaging nigral pathology and clinical progression in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[14] A. Schnitzler,et al. Manual MRI morphometry in Parkinsonian syndromes , 2017, Movement disorders : official journal of the Movement Disorder Society.
[15] D. Jennings,et al. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter–Deficit Prodromal Cohort , 2017, JAMA neurology.
[16] E. Kim,et al. Drug-induced Parkinsonism versus Idiopathic Parkinson Disease: Utility of Nigrosome 1 with 3-T Imaging. , 2016, Radiology.
[17] P. Mir,et al. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[18] Dorothee P Auer,et al. In Vivo Assessment of Brainstem Depigmentation in Parkinson Disease: Potential as a Severity Marker for Multicenter Studies. , 2017, Radiology.
[19] Michael Schocke,et al. Dorsolateral nigral hyperintensity on 3.0T susceptibility‐weighted imaging in neurodegenerative Parkinsonism , 2015, Movement disorders : official journal of the Movement Disorder Society.
[20] T. Simuni,et al. Can loss of the swallow tail sign help distinguish between Parkinson Disease and the Parkinson-Plus syndromes? , 2017, Clinical imaging.
[21] Dong-Hyun Kim,et al. Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map‐weighted imaging (SMWI) , 2017, Journal of magnetic resonance imaging : JMRI.
[22] Stanley Fahn,et al. Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease , 2018, npj Parkinson's Disease.
[23] A. van Cappellen van Walsum,et al. Nigrosome-1 on Susceptibility Weighted Imaging to Differentiate Parkinson’s Disease From Atypical Parkinsonism: An In Vivo and Ex Vivo Pilot Study , 2016, Polish journal of radiology.
[24] W. Poewe,et al. Meta‐analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.
[25] E. Kim,et al. Initial diagnostic workup of parkinsonism: Dopamine transporter positron emission tomography versus susceptibility map-weighted imaging at 3T. , 2019, Parkinsonism & related disorders.
[26] G. Deuschl,et al. MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[27] Dosik Hwang,et al. Susceptibility map‐weighted imaging (SMWI) for neuroimaging , 2014, Magnetic resonance in medicine.
[28] S. Gacinovic,et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group , 2000, Movement disorders : official journal of the Movement Disorder Society.
[29] F. Yang,et al. Universality analysis of the existence of substantia nigra "swallow tail" appearance of non-Parkinson patients in 3T SWI. , 2016, European review for medical and pharmacological sciences.
[30] J S Thornton,et al. 9.4T MR microscopy of the substantia nigra with pathological validation in controls and disease. , 2017, NeuroImage. Clinical.
[31] Dorothee P. Auer,et al. The ‘Swallow Tail’ Appearance of the Healthy Nigrosome – A New Accurate Test of Parkinson's Disease: A Case-Control and Retrospective Cross-Sectional MRI Study at 3T , 2014, PloS one.
[32] A. Graybiel,et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.
[33] J. Rowe,et al. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? , 2017, Movement disorders : official journal of the Movement Disorder Society.
[34] R. Djaldetti,et al. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] Yasuo Terayama,et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease , 2006, Neuroreport.
[36] Dorothee P Auer,et al. T1‐Weighted MRI shows stage‐dependent substantia nigra signal loss in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[37] Martin Styner,et al. Combined R2* and Diffusion Tensor Imaging Changes in the Substantia Nigra in Parkinson's Disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[38] Eung Yeop Kim,et al. Differential involvement of nigral subregions in idiopathic parkinson's disease , 2018, Human brain mapping.
[39] J. Cummings,et al. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. , 2011, Brain : a journal of neurology.
[40] A. Graybiel,et al. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. , 1999, Brain : a journal of neurology.
[41] M. Tosetti,et al. Comparison of 3T and 7T Susceptibility-Weighted Angiography of the Substantia Nigra in Diagnosing Parkinson Disease , 2015, American Journal of Neuroradiology.
[42] D. Korzhevskii,et al. Immunohistochemical Characteristics of Neurons in the Substantia Nigra of the Human Brain , 2018, Neuroscience and Behavioral Physiology.
[43] W. Poewe,et al. The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. , 2018, Parkinsonism & related disorders.
[44] Francesco Fera,et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. , 2008, Radiology.
[45] S. Fahn. Description of Parkinson's Disease as a Clinical Syndrome , 2003, Annals of the New York Academy of Sciences.
[46] R. Mailman,et al. Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients , 2018, Movement disorders : official journal of the Movement Disorder Society.
[47] J. Lee,et al. Nigrosome 1 Detection at 3T MRI for the Diagnosis of Early-Stage Idiopathic Parkinson Disease: Assessment of Diagnostic Accuracy and Agreement on Imaging Asymmetry and Clinical Laterality , 2015, American Journal of Neuroradiology.
[48] Xiangchuan Chen,et al. A multicontrast approach for comprehensive imaging of substantia nigra , 2015, NeuroImage.